DUBLIN, June 26, 2023– Report “Restricted Peptide Drug Market – Global and Regional Analysis: Focus on Peptide Types, Products and Regional Analysis – Analysis and Forecast, 2024-2040″ .
After the earliest market launch of the first restricted peptide drug, the global restricted drug market is predicted to grow from 2024 to 2040. The market size is expected to reach $60M in 2024 and $17.38B in 2040, with a CAGR of 38.94% over the forecast period 2025-2040.
The global restricted peptide drug market is expected to experience tremendous growth during the forecast period from 2025 to 2040, driven in large part by the promise of a new breakthrough restricted peptide pipeline that is no longer limited to receptor targets. Advances in chemical technology, advances in the commercialization of synthetic peptide therapeutics in recent years, and the affordable prices achieved by these biomolecules in various diseases are some additional factors contributing to the projected growth over the forecast period.
The analysis of short-term and long-term impacts is carried out on factors that significantly affect the market, namely, drivers, constraints and opportunities. The short-term assessment considers the period 2020-2025 and the long-term assessment considers the period 2026-2040.
Key developments and strategies adopted by some of the key players in this market have been included in the impact analysis evaluation. In addition, these key developments are evaluated to understand future opportunities for integrating advanced technologies to achieve superior results. In addition, the approvals and launches of companies and patent agencies are also taken into account when assessing the dynamics of the global market for peptide-restricted peptide drugs.
Demand Factors and Constraints The following are the demand factors for the global Peptide Dependence Inhibitors market:
4 Market Overview 4.1 Introduction 4.1.1 Structure and Design of Restricted Peptides 4.1.2 Types of Restricted Peptides 4.2 Evolution of Restricted Peptides 4.3 Development of Restricted Peptides as Drugs 4.4 Potential Therapeutic Areas 4.5 Value Chain – Key Stakeholders 4.6 Key Industry Trends (by Region) ) 4.7 Key industry trends along the path of introduction 4.8 Key industry trends – technological progress 4.9 Current market size and growth potential, USD billion, 2024-2040 and renewal for companies producing restricted-use peptide drugs
5 Properties of conformationally restricted peptides 5.1 Properties of conformationally restricted peptides 5.2 Synthesis of restricted peptides 5.2.1 Chemical ligation of peptides and bridging 5.2.2 Chemical ligation of peptides to scaffolds (CLIPS) 5.2.3 Crosslinking of peptides 5.2.4 Platform for peptide discovery (5.2.5 Liquid-Phase Peptide Synthesis (LPPS) 5.2.6 Solid-Phase Peptide Synthesis (SPPS) 5.3 Advances in Peptide Technology 5.3.1 Peptide Synthesis Using Microfluidics 5.3.2 Solid-Phase Peptide Synthesis Using Microwaves 5.4 Peptide Display and Select System
6 Industry Data 6.1 Overview 6.2 Issues with Regulatory Approval Pathways for Restricted Peptides 6.3 Regulatory Scenarios for Restricted Peptides 6.4 US Regulatory Requirements and Structure 6.4.1 Clinical Trial Authorization 6.4.2 Marketing Authorization 6.4.3 US FDA Submission Guidelines NDA 6.4.4 After authorization rule 6.5 European legal requirements and framework 6.5.1 EMA license application process 6.5.2 Centralized procedures 6.5.3 Decentralized procedures 6.5.4 Mutual recognition procedures 6.5.5 National procedures 6.6 Legal requirements and frameworks in Asia -Pacific region 6.6. 1 Legal requirements and structure in Japan 6.7 Reimbursement scenarios 6.7.1 Autoimmune disease reimbursement scenarios 6.7.2 Cancer reimbursement scenarios 6.7.3 Rare disease reimbursement scenarios
7 Market Dynamics 7.1 Impact Analysis 7.2 Market Factors 7.2.1 Increased Binding Affinity and Cellular Uptake 7.2.2 Development of Limited Synthetic Approaches 7.2.3 Limitations of Conventional Peptides 7.2.4 Increase in Public and Private Funding 7.2.4.1 Funding of Private Companies 7.2.4 . 2 Funding by listed companies 7.2.4.3 Funding by public institutions 7.3 Market constraints 7.3.1 Increasing competition for biologics 7.3.2 Risk of immunogenic effects and sub-optimal properties of ADME 7.4 Market opportunities 7.4.1 Limited peptides in drug discovery 7.4.2 Various applications nervous system and cancer therapy
8 Competitive landscape 8.1 Overview of the competitive landscape 8.1.1 Key developments 8.1.2 Regulatory and legal activities 8.1.3 Mergers and acquisitions 8.1.4 Synergy activities 8.1.5 Financial activities 8.1.6 Clinical development
9 Global market of restraining peptide drugs (by directions), mln USD, 2024–2040 9.1 Clinical Trial Design for Restraining Peptide Therapies 9.1.1 Potential Phase II Therapies II) 9.1.2.3 Efficacy, Safety, and Tolerability Data (Stage 1) 9.1.2.4 Nonclinical Studies of BT5528 9.1.3 PN-9439.1.3.1 Product Introduction 9.1.3.2 Design studies (Phase 2) 9.1.3.3 Efficacy, safety and tolerability data (Phase II) 9.1.4 PN-2359.1.4.1 Product introduction 9.1.4.2 Study design (Phase IIb) 9.1.4.3 Efficacy, safety and tolerability data (Phase IIb) 9.1.5 Rusfertide (PTG-300) 9.1.5.1 Product overview 9.1.5.2 Study design (Phase II) 9.1.5.3 Efficacy, safety and tolerability data (Phase IIa) 9.1.6 Potential Phase III drugs 9.1.7 Zilukoplan (RA101495) 9.1.7.1 Product overview 9.1.7.2 Study design (Phase III) 9.1.7.3 Efficacy, safety and tolerability data (Phase III) 9.1.7.4 Pharmacokinetic and pharmacodynamic profile of Zilucoplan (Phase I) 9.1.8 Rusfertide (PTG- 300) 9.1.8.1 Product overview 9.1.8.2 Study design (Phase III) 9.1.8.3 Efficacy, safety and tolerability data (Phase II) 9.2 Analysis of the development dynamics of the global market for restricted peptide drugs, USD million, 2024-2040 success 9.2.2.2 Cost of API production (CDMO)
10 Global market for drugs with limited peptide action (by peptide type), US$ mln, 2024–2040 linked peptide (DRP))
11 Global market for restricted peptide drugs (by potential products), mln USD, 2024–2040 (RA101495) 11.1.2.1 API production (domestic) 11.1.2.2 API demand forecast for 2024-2040 11.1.3 Rusfertide (PTG-300) 11.1.3.1 API Production (Outsourcing) Cost 11.1.4 PN-94311.1.4.1 API Production (Outsourcing) 11.1.4.2 API Demand Forecast 2024-2040
Post time: Jul-06-2023